Document Detail


Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects.
MedLine Citation:
PMID:  8303624     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: The cysteinyl leukotrienes (LTC4, LTD4, and LTE4) have been shown to mediate airway obstruction evoked by several factors which trigger asthmatic reactions--for example, allergen and exercise. Accordingly, drugs which block the action or formation of these leukotrienes are being evaluated as a new treatment of asthma. Elevated production of leukotrienes has been reported in asthmatic subjects who are intolerant to aspirin and related nonsteroidal anti-inflammatory drugs. In this study the influence of the specific leukotriene receptor antagonist MK-0679 was tested on basal airway function in asthmatic patients with documented aspirin intolerance. METHODS: The eight subjects in the study had a mean baseline FEV1 of 78% predicted (range 58-99%) and six required treatment with inhaled glucocorticosteroids (400-1200 micrograms budesonide/beclomethasone daily). On two separate days the subjects received either 825 mg MK-0679 or placebo, orally in a double blind, randomised, crossover design. RESULTS: The leukotriene antagonist MK-0679 caused bronchodilation which lasted for at least nine hours. The average peak improvement in FEV1 was 18% above the predrug baseline, but the bronchodilator response varied between 34% and 5% and was found to correlate strongly with the severity of asthma and aspirin sensitivity. CONCLUSIONS: The findings indicate that ongoing leukotriene production may be one cause of persistent airway obstruction in aspirin sensitive asthmatic subjects and that they may benefit from treatment with a leukotriene receptor antagonist.
Authors:
B Dahl?n; D J Margolskee; O Zetterstr?m; S E Dahl?n
Related Documents :
23477784 - Advances in anticancer antibody-drug conjugates and immunotoxins.
17828434 - Myo-inositol-1-phosphate (mip) synthase inhibition: in-vivo study in rats.
24032744 - Targeting the abcg2-overexpressing multidrug resistant (mdr) cancer cells by pparγ ago...
4854 - Inhibition of prostaglandin biosynthesis by sulphasalazine and its metabolites.
15710314 - Add-on therapy with topiramate in progressive myoclonic epilepsy.
23742764 - In vivo efficacy of pf1022a and nicotinic acetylcholine receptor agonists alone and in ...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Thorax     Volume:  48     ISSN:  0040-6376     ISO Abbreviation:  Thorax     Publication Date:  1993 Dec 
Date Detail:
Created Date:  1994-03-10     Completed Date:  1994-03-10     Revised Date:  2010-03-24    
Medline Journal Info:
Nlm Unique ID:  0417353     Medline TA:  Thorax     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  1205-10     Citation Subset:  IM    
Affiliation:
Department of Thoracic Medicine, Karolinska Hospital, Stockholm, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Airway Obstruction / drug therapy,  physiopathology
Aspirin / adverse effects
Asthma / drug therapy*,  physiopathology
Bronchi / drug effects
Double-Blind Method
Female
Forced Expiratory Volume
Humans
Lung / drug effects*,  physiopathology
Male
Middle Aged
Propionates / therapeutic use*
Quinolines / therapeutic use*
SRS-A / antagonists & inhibitors*
Chemical
Reg. No./Substance:
0/Propionates; 0/Quinolines; 0/SRS-A; 115104-28-4/verlukast; 50-78-2/Aspirin
Comments/Corrections
Comment In:
Thorax. 1993 Dec;48(12):1189-90   [PMID:  8303620 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Histological study of the cranial neural folds of mice genetically liable to exencephaly.
Next Document:  How many times per day should peak expiratory flow rates be assessed when investigating occupational...